Posted by Michael Wonder on 13 Sep 2022
Hanmi Pharmaceutical scores its first FDA approval
13 September 2022 - Hanmi Pharmaceutical has scored its first approval from the US Food and Drug Administration with its novel biomedicine Rolontis.
Rolontis -- Hanmi Pharmaceutical's treatment for neutropenia, a disease that occurs when a specific type of white blood cells is lacking so that the body cannot fight infections, especially those caused by bacteria -- was given the FDA’s approval on Friday, according to the Korean firm’s US partner Spectrum Pharmaceuticals’ announcement.
